The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

CompletedOBSERVATIONAL
Enrollment

99,481

Participants

Timeline

Start Date

February 28, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

April 1, 2024

Conditions
NeoplasmsCancer
Trial Locations (35)

23229

Sarah Cannon Research Institute, Richmond

23235

Sarah Cannon Research Institute, Richmond

24153

Sarah Cannon Research Institute, Salem

29406

Sarah Cannon Research Institute, Charleston

30078

Sarah Cannon Research Institute, Snellville

32224

Mayo Clinic, Jacksonville

Mayo Clinic, Rochester

37076

Sarah Cannon Research Institute, Hermitage

37203

Sarah Cannon Research Institute, Nashville

44011

Cleveland Clinic, Avon

44122

Cleveland Clinic, Beachwood

44195

Cleveland Clinic, Cleveland

48126

Henry Ford Health System, Dearborn

48150

Henry Ford Health System, Livonia

48202

Henry Ford Health System, Detroit

48326

Henry Ford Health System, Grosse Pointe Farms

54601

Mayo Clinic, La Crosse

54702

Mayo Clinic, Eau Claire

64057

Sarah Cannon Research Institute, Independence

66209

Sarah Cannon Research Institute, Overland Park

75069

Sarah Cannon Research Institute, McKinney

84124

Sarah Cannon Research Institute, Salt Lake City

85054

Mayo Clinic, Phoenix

85258

Scottsdale Medical Imaging Research, Scottsdale

94040

Sutter Health, Mountain View

94118

Sutter Health, San Francisco

94301

Sutter Health, Palo Alto

94401

Sutter Health, San Mateo

94609

Sutter Health, Oakland

95062

Sutter Health, Santa Cruz

95403

Sutter Health, Santa Rosa

95630

Sutter Health, Folsom

95661

Sutter Health, Roseville

95758

Sutter Health, Elk Grove

95816

Sutter Health, Sacramento

All Listed Sponsors
lead

GRAIL, Inc.

INDUSTRY

NCT03085888 - The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types | Biotech Hunter | Biotech Hunter